Article
Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2013
Bejar Rafael, Tiu Ramon V, Sekeres Mikkael A, Komrokji Rami S
Abstract excerpt
Significant advances have been achieved in understanding and treating myelodysplastic syndromes (MDS) in the past decade. For the first time, three drugs were approved specifically for this disease. Novel sequencing techniques have expanded our understanding of the molecular basis of MDS. Several clinically significant recurrent gene mutations have been identified. The classification and risk stratification of...
Topics
- Antineoplastic Agents
- Biomarkers, Tumor
- Decision Support Techniques
- Drug Design
- Genetic Predisposition to Disease
- Humans
- Molecular Diagnostic Techniques
- Molecular Targeted Therapy
- Mutation
- Myelodysplastic Syndromes